Cargando…

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients

BACKGROUND: Belatacept-based therapy in kidney transplant recipient has been shown to increase long-term renal allograft and patient survival compared with calcineurin inhibitor–based therapy, however, with an increased risk of acute T cell-mediated rejection (aTCMR). An improved understanding of co...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Zwan, Marieke, Baan, Carla C., Colvin, Robert B., Smith, Rex N., White, Rebecca A., Ndishabandi, Dorothy, Nigg, Alex L., van den Bosch, Thierry P.P., de Graav, Gretchen N., Clahsen-van Groningen, Marian C., Hesselink, Dennis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Kidney Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324913/ https://www.ncbi.nlm.nih.gov/pubmed/30656216 http://dx.doi.org/10.1097/TXD.0000000000000857

Ejemplares similares

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

Mast Cells in Kidney Transplant Biopsies With Borderline T Cell-mediated Rejection and Their Relation to Chronicity
por: Varol, Hilal, et al.
Publicado: (2023)

Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2023)

Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
por: Francke, Marith I., et al.
Publicado: (2021)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function
por: Mahaparn, Irisa, et al.
Publicado: (2023)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
por: Johnson, Aileen C., et al.
Publicado: (2023)

A Combined microRNA and Chemokine Profile in Urine to Identify Rejection After Kidney Transplantation
por: Gielis, Els M., et al.
Publicado: (2021)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Efficacy of Prolonged-release Tacrolimus After Conversion From Immediate-release Tacrolimus in Kidney Transplantation: A Retrospective Analysis of Long-term Outcomes From the ADMIRAD Study
por: Kuypers, Dirk, et al.
Publicado: (2023)

Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome
por: van den Hoogen, Martijn W.F., et al.
Publicado: (2017)

Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury
por: Bijkerk, Roel, et al.
Publicado: (2017)

Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Baan, Carla C., et al.
Publicado: (2018)

Kidney Rejection Following Simultaneous Liver-kidney Transplantation
por: Shah, Sapna, et al.
Publicado: (2020)

Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
por: Tedesco-Silva, Helio, et al.
Publicado: (2016)

Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation
por: Mo, Hyejin, et al.
Publicado: (2019)

Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies
por: Shaw, James, et al.
Publicado: (2019)

High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients
por: Goodall, Dawn L., et al.
Publicado: (2017)

Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017)

Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis
por: Wehmeier, Caroline, et al.
Publicado: (2017)

Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients
por: Jordan, Stanley C., et al.
Publicado: (2018)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts
por: Abu Jawdeh, Bassam G., et al.
Publicado: (2022)

Early Versus Late Conversion From Immediate to Prolonged-Release Tacrolimus After Renal Transplantation: Clinical Effects and Treatment Costs
por: Mendonça, Luís, et al.
Publicado: (2018)

Clinical Implications of Tacrolimus Time in Therapeutic Range and Intrapatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal
por: Pierce, Dana R., et al.
Publicado: (2021)

Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial
por: Gwinner, Wilfried, et al.
Publicado: (2022)

Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
por: Pottebaum, April A., et al.
Publicado: (2020)

Acute Kidney Allograft Rejection Following Coronavirus mRNA Vaccination: A Case Report
por: Bau, Jason T., et al.
Publicado: (2022)

Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
por: Abedini, Sadollah, et al.
Publicado: (2018)

Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study
por: Zheng, YuanPu, et al.
Publicado: (2019)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

Response to Treatment for Chronic-active T Cell–mediated Rejection in Kidney Transplantation: A Report of 3 Cases
por: Noguchi, Hiroshi, et al.
Publicado: (2020)

Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss
por: Petr, Vojtech, et al.
Publicado: (2021)

How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy
por: Aziz, Fahad, et al.
Publicado: (2022)

Nuclear Factor of Activated T Cell-regulated Cytokine Gene Expression for Adjustment of Tacrolimus in Kidney Transplant Recipients: A Randomized Controlled Pilot Trial
por: Webber, Allison B., et al.
Publicado: (2018)

The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation
por: Do Nguyen, Hung Thanh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ib8r3u51g0sc5hfb13hh95p2pe